SecBot SecBot
8-K ·Filed Nov 5, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 16h ago SEC0001818794-26-000013
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the January 21, 2027 PDUFA date for z-rostudirsen; approval would mark Dyne's first commercial product. The wider net loss and increased spending on manufacturing and Phase 3 trials are expected for a pre-commercial biotech. Monitor the ACHIEVE REC topline data in Q1 2027 for z-basivarsen as the next major pipeline catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

DYN drug pipeline →

z-rostudirsen

▲ Bullish Named in this 8-K
Impact
Phase
Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
Time to market
Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
Next catalyst
PDUFA date · Jan 21, 2027 65d

What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.

Price Chart

Loading chart...

Executive Summary

The BLA for z-rostudirsen in DMD is under FDA priority review with a PDUFA date of January 21, 2027, and topline data from the ACHIEVE REC for z-basivarsen in DM1 is expected in Q1 2027. Cash of $1.134B is expected to fund operations into Q2 2028.

Key Facts

  • Cash, cash equivalents and marketable securities of $1.134B as of September 30, 2026, sufficient into Q2 2028
  • BLA for z-rostudirsen (exon 51 DMD) under FDA priority review with PDUFA target action date of January 21, 2027
  • Topline data from ACHIEVE registrational expansion cohort for z-basivarsen (DM1) planned for Q1 2027
  • R&D expenses increased to $161.7M from $97.2M YoY, driven by manufacturing and Phase 3 trial costs
  • G&A expenses increased to $35.3M from $16.7M YoY due to launch preparation and headcount growth

Financial Impact

Net loss of $193.6M in Q3 2026, $85.6M wider than Q3 2025; cash burn rate increased significantly

net losscash positionR&D expensesG&A expenses

Risk Factors

  • FDA may not approve z-rostudirsen by the PDUFA date or may require additional data
  • Z-basivarsen ACHIEVE REC topline data in Q1 2027 may not support BLA submission
  • Cash burn rate is accelerating; $1.134B may not be sufficient if timelines slip or additional trials are needed
  • Competing therapies for DMD and DM1 could limit commercial potential if approved

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001818794-26-000013
Document: dyn-20261105.htm0001818794-26-000013
Document: 0001818794-26-000013-index-headers.html0001818794-26-000013
Document: 0001818794-26-000013-index.html0001818794-26-000013
Document: 0001818794-26-000013.txt0001818794-26-000013
8-K Data (Synthetic)0001818794-26-000013

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026